| | | | | | | | s | heet <u>1</u> of <u>1</u> . |
|---|----|--------------------|---------|-------------|--|-------|---------------------|-----------------------------|
| Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | | | | | ATTY. DOCKET NO. P31855C3 PRED. SERIAL NO. 10/346,947 10/80059 | | | * |
| | | | | | APPLICANT Buckingham et al. | | | |
| | | | | | PRED. FILING DATE 17 January 2003 | | PRED. GROUP 1614 | |
| | | | · | J.S. PATENT | DOCUMENTS | | | |
| Examiner Initial | | Document Number | Date | | Name | Class | Subclass | Filing Date If Appropriate |
| (للل | AA | 4.895.862 | 1/23/90 | Alessi et | al | 514 | 360 | |

| | | | FOR | REIGN PATENT DOCUMENT | S | | | |
|-----|----|--------------------|---------|-----------------------|-------|----------|---------------------|--------------|
| | | Document Number | Date | Country | Class | Subclass | <u>Irans</u> Yes | lation No |
| 160 | AC | EP 0 749 751 | 12/1996 | EPO | | | | |
| | AD | WO 93/03724 | 03/1993 | PCT | | | _ | |
| | AE | WO 98/36755 | 8/1998 | PCT | | | | |
|) | AF | EP 0 861 666 | 09/1998 | EPO | | | | |
| le | AG | WO 95/21608 | 08/1995 | PCT | | | | |

Zask et al.

548

183

11/26/91

AB 5,068,342

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AH Donnelly et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and New Pharmacological Approaches to Metabolism", Br. J. Clin Pharm., 37: 311-320 (1994). ΑI Jackson et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes". Diabetes, 36: 632-640 (1987). G. Williams, "Management of Non-Insulin-Dependent Diabetes Mellitus", The Lancet, 343: AJ 95-100 (1994). Kelley et al., "Troglitazone", Current Opin. Endocrinol. & Diabetes, 5(2): 90-96 (1998). ΑK Scheen et al., "Oral Antidiabetic Agents, A Guide to Selection". Dis. Management, 55(2): AL 225-236 (XP002080821). AM A.J. Scheen, "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Achievements and Future Developments". Drugs, 54(3): 355-368 (1997). Iwamoto et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Therapy Alone". Diabetic Med., 13(4): 365-370 (1996). K. Doi, "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Development". AO J. Japan Diabetes Sci., 3(S1): 962-973 (1990). ΑP N. Hotta, "How to Select and Use Oral Hypoglycemic Agents". Chronic Dis., 6(1): 1-9 (1995).AQ H. Lebovitz, "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". Diabetes Care, 17(12): 1542-1544 (1994). AR Lehmann et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ)". J. Biol. Chem., 270: 12953-12956 (1995). Hofmann et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers", AS 16 Diabetes Care, 15(8): 1075-1078 (1992) EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

n:\kls\cases\p31855c3\pto 1449 form.doc